A: Sensitivity to dasatinib in healthy donor control, FLT3 mutated and non-FLT3 mutated AML patient samples; B: Sensitivity to MEK inhibitors in healthy donor control, Ras mutated and non-Ras mutated samples expressed as drug sensitivity scores (DSS).